Business
Bioasis Establishes U.S. Presence with Office in Connecticut
Bioasis Establishes U.S. Presence with Office in Connecticut.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical \n company focused on the delivery of therapeutics across the blood-brain \n barrier (BBB) and into the central nervous system for the treatment of \n neurological diseases and disorders, today announced the establishment \n of its U.S. office in Guilford, Conn. Additionally, the Company has \n launched its new corporate website, bioasis.us.\n \n \n “Establishing a strong presence in the U.S. is an important next step in \n the evolution of Bioasis,” said Mark Day, Ph.D., president and chief \n executive officer. “The greater New Haven area is in close proximity to \n both Boston and New York. The new U.S. office provides a physical \n location that is at the cross roads of pharma, biotech and academia. It \n will increase the exposure of our company and provide access to a broad \n pool of talent and strategic resources.”\n \n \n Following a strategic rebranding process, Bioasis has launched its new \n website, bioasis.us. \n The new website reflects a new array of branding elements, including xB3™, \n the Company’s proprietary platform technology for the delivery of \n neurological treatments across the BBB, and a modernized logo. Bioasis’ \n new corporate branding is an additional step in the transformation that \n has been taking place at Bioasis over the past six months.\n \n \n The new Bioasis site, which has been optimized for both desktop and \n mobile users, more accurately tells the company’s story and clearly \n highlights the company’s mission to develop symptomatic and \n disease-modifying treatments for brain-related diseases and disorders. \n Visitors to the website are able to efficiently access information on \n Bioasis, the xB3 platform, the Company’s in-house development \n programs and other corporate information.\n \n \n “Bioasis is evolving and we want all aspects of our corporate messaging \n to reflect these changes moving forward,” said Dr. Day. “Our new \n branding, website and office location are a part of our move to more \n fully engage with potential biotech and pharmaceutical partners, better \n position the company for its expansion into the U.S. and to execute our \n corporate strategies for the advancement of the xB3 platform \n and t...